SALSA MLPA P308 MET probemix - 50 reactions

application: Papillary renal carcinoma, various cancers
region: MET 7q31, PTEN 10q23.31, LRRK2 12q12 Detailní informace

Cena s DPH € 573.54
Cena bez DPH € 474.00
 50 react
Dostupnost Skladem
Kód produktu P308-050R

Nejnovější informace o produktu naleznete exklusivně na stránkách výrobce MRC-Holland www.mlpa.com (nové okno)

Detailní popis SALSA MLPA P308 MET probemix - 50 reactions

P308-025R SALSA MLPA P308 MET probemix – 50 rxn

description
The receptor tyrosine kinase MET (also known as hepatocyte growth factor receptor (HGFR)) is frequently amplified in human tumours. This results in high cell surface densities and constitutive activation even in the absence of growth factor stimulation by its endogenous ligand, hepatocyte growth factor (HGF). MET is essential for survival and long-distance migration of epithelial and myogenic precursors during embryogenesis. Cancer cells hijack this mechanism for invasion and metastasis. Aberrant MET activation occurs in many types of cancer. Resulting from multiple mechanisms many carcinomas overexpress MET and the surrounding stroma overexpress HGF.

MET gene amplifications are detected in a wide range of tumour types e.g. brain tumours, gastric cancer and lung tumours (Peters S. & Adjei A.A. 2012. Nat. Rev. Clin. Oncol. 9;314-26). Patients with papillary renal carcinomas carry both germline and somatic point mutations in MET (Schmidt L et al. 1997. Nat Genet. 16:68-73; Schmidt L et al. 1999. Oncogene. 18:2343-50). The chromosomal amplification of a leucine-rich repeat kinase-1 (LRRK2) is required for oncogenic MET signalling in papillary renal and in thyroid carcinomas and act downstream of MET activation (Looyenga BD et al. 2011. PNAS 108;1439-44). The loss of tumour suppressor protein PTEN and amplification of MET can be an alternative mechanisms for primary resistance for tyrosine kinase inhibitors (EGFR-TKIs) (Engelman JA et al. 2007. Science. 316:1039-43; Sos ML et al. 2009 Cancer Res, 69:3256-61).

The MET gene (21 exons) spans ~126 kb of genomic DNA and is located at 7q31.2, 43 Mb from the q-telomere. The PTEN gene (9 exons) spans ~105 kb of genomic DNA and is located at 10q23.31, 46 Mb from the q-telomere. The LRRK2 gene (51 exons) spans ~144 kb of genomic DNA and is also located at 12q12, 93 Mb from the q-telomere. P308 probemix contains 33 probes for these three genes, including two flanking probes for MET. These genes are suggested to be of diagnostic and prognostic relevance in papillary renal carcinomas and in a variety of other tumours. The P308 probemix contains at least one probe for each exon of the MET gene. In addition, two probes flanking MET (CAV2 upstream and CFTR downstream) are included in the mix. For PTEN, probes for exon 2, 3, 5 and 9 are included. For LRRK2, probes for exon 1, 10, 15 and 41 are present. In addition, 14 reference probes have been included in this probemix, detecting 13 different autosomal chromosomal locations, which are generally relatively quiet in tumour samples. However, it should be noticed that tumour genomes can harbour multiple numerical and structural aberrations, which can complicate interpretation of these reference probes.

This SALSA® MLPA® probemix is designed to detect copy number changes of one or more sequences in the above mentioned genes and chromosomal regions. Heterozygous deletions of recognition sequences should give a 35-50% reduced relative peak area of the amplification product of that probe. Note that a mutation or polymorphism (e.g. SNP) in the sequence detected by a probe can also cause a reduction in relative peak area, even when not located exactly on the ligation site! In addition, some probe signals are more sensitive to sample purity and small changes in experimental conditions. Therefore, single probe deletions or duplications detected by MLPA should always be confirmed by other methods or by MLPA probemixes with higher resolution in the gene or chromosomal area of interest. Users should always verify the latest scientific literature when interpreting their findings.

Kontaktujte nás

BIOGEN PRAHA s.r.o.
Ke sv. Izidoru 2293/4A
140 00 PRAHA 4

Tel.: +420 241 401 693
Fax: +420 241 401 694
E-mail: biogen@biogen.cz

Novinky na e-mail